COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,705 Articles (22,913 medRxiv, 8,792 bioRxiv)

Most recent first Previous |  Page 2969: Articles 29681-29690  | Next

A Web-based, Mobile Responsive Application to Screen Healthcare Workers for COVID Symptoms: Descriptive Study
Zhang, H., Dimitrov, D., Simpson, L., Singh, B., Plaks, N., Penney, S., Charles, J., Sheehan, R., Flammini, S., Murphy, S., Landman, A.
10.1101/2020.04.17.20069211 — Posted: 2020-04-22
Statistical and network-based analysis of Italian COVID-19 data: communities detection and temporal evolution
Milano, M., Cannataro, M.
10.1101/2020.04.17.20068916 — Posted: 2020-04-22
A Chronological and Geographical Analysis of Personal Reports of COVID-19 on Twitter
Klein, A., Magge, A., O'Connor, K., Cai, H., Weissenbacher, D., Gonzalez-Hernandez, G.
10.1101/2020.04.19.20069948 — Posted: 2020-04-22 Discussion: Onsite
The proportion of deaths cases in confirmed patients of COVID-19 is still increasing for cumulative cases reported up to 14 April 2020
Scheuerl, T.
10.1101/2020.04.17.20068908 — Posted: 2020-04-22
Years of life lost due to the psychosocial consequences of COVID19 mitigation strategies based on Swiss data
Moser, D. A., Glaus, J., Frangou, S., Schechter, D. S.
10.1101/2020.04.17.20069716 — Posted: 2020-04-22 Discussion: Onsite
The effect of BCG vaccination on COVID-19 examined by a statistical approach: no positive results from the Diamond Princess and cross-national differences previously reported by world-wide comparisons are flawed in several ways
Asahara, M.
10.1101/2020.04.17.20068601 — Posted: 2020-04-22 Discussion: Onsite
Mental health outcomes among front and second line health workers associated with the COVID-19 pandemic in Italy.
Rossi, R., Socci, V., Pacitti, F., Di Lorenzo, G., Di Marco, A., Siracusano, A., Rossi, A.
10.1101/2020.04.16.20067801 — Posted: 2020-04-22
Hydroxychloroquine for the management of COVID-19: Hope or Hype? A Systematic review of the current evidence
Suranagi, U. D., Rehan, H. S., Goyal, N.
10.1101/2020.04.16.20068205 — Posted: 2020-04-22 Discussion: Onsite
Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., Neary, M., Sharp, J., Liptrott, N. J., Valentijn, A., David, C., Rannard, S. P., O'Neill, P., Aljayyoussi, G., Pennington, S., Ward, S. A., Back, D. J., Khoo, S. H., Bray, P. G., Biagini, G., Owen, A.
10.1101/2020.04.16.20068379 — Posted: 2020-04-22
"No test is better than a bad test": Impact of diagnostic uncertainty in mass testing on the spread of Covid-19
Gray, N., Calleja, D., Wimbush, A., Miralles-Dolz, E., Gray, A., De-Angelis, M., Derrer-Merk, E., Oparaji, B. U., Stepanov, V., Clearkin, L., Ferson, S.
10.1101/2020.04.16.20067884 — Posted: 2020-04-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).